p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study

Zhang,Peng; Wu,Song‑Ke; Wang,Ying; Fan,Zi‑Xuan; Li,Chu‑Rong; Feng,Mei; Xu,Peng; Wang,Wei‑Dong; Lang,Jin‑Yi

doi:10.3892/ol.2014.2631

p53, MDM2, eIF4E and EGFR expression in nasopharyngeal carcinoma and their correlation with clinicopathological characteristics and prognosis: A retrospective study

Authors:
- Peng Zhang
- Song‑Ke Wu
- Ying Wang
- Zi‑Xuan Fan
- Chu‑Rong Li
- Mei Feng
- Peng Xu
- Wei‑Dong Wang
- Jin‑Yi Lang
View Affiliations

Affiliations: Department of Radiation Oncology, Sichuan Provincial Cancer Hospital, Chengdu, Sichuan, 610041, P.R. China, Department of Oncology, Cangxi People's Hospital, Guangyuan, Sichuan, 618400, P.R. China, Department of Pathology, Sichuan Provincial Cancer Hospital, Chengdu, Sichuan 610041, P.R. China
Published online on: October 24, 2014 https://doi.org/10.3892/ol.2014.2631
Pages: 113-118

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the expression of p53, mouse double minute 2 homolog (MDM2), eukaryotic translation initiation factor 4E (eIF4E), and epidermal growth factor receptor (EGFR) were investigated in nasopharyngeal carcinoma (NPC), and the correlation between their expression and clinicopathological characteristics and prognosis was analyzed. The medical records of 96 NPC patients who had undergone biopsy prior to radical radiotherapy and chemotherapy between 2005 and 2009 were reviewed, retrospectively. All patients received intensity‑modulated radiotherapy with concurrent platinum‑based chemotherapy. Patients were followed‑up for three years. Streptavidin‑peroxidase immunohistochemistry was used to evaluate the expression of p53, MDM2, eIF4E and EGFR in NPC biopsy specimens, and the association between their expression and clinical parameters and survival was analyzed. The p53, MDM2, eIF4E and EGFR expression rates were 65.6% (63/96), 79.16% (76/96), 77.08% (74/96) and 89.5% (86/96), respectively. p53 (χ2,20.322; P=0.001) and EGFR (χ2,8.337; P=0.005) expression were found to correlate with T stage, whereas MDM2 (χ2,16.361; P=0.001) expression was found to correlate with lymph node metastasis. p53 expression was found to inversely correlate with MDM2 expression (r, ‑3.24; P<0.05). Three‑year survival rates were lower in p53‑positive (76.2%) patients when compared with p53‑negative (93.9%) patients. In addition, three‑year survival rates were lower in EGFR‑positive (75.8%) patients than in EGFR‑negative patients (91.2%). The Cox proportional‑hazards regression model revealed that p53 (β,‑0.455; χ2,5.491; P=0.019) and EGFR (β, 3.93; χ2, 11.95; P=0.001) expression were independent prognostic factors. Thus, it was hypothesized that p53 and EGFR expression present potential unfavorable prognostic markers for patients with NPC.

View Figures

View References

1	Ho FC, Tham IW, Earnest A, et al: Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC Cancer. 12:982012. View Article : Google Scholar : PubMed/NCBI
2	Golubovskaya VM, Conway-Dorsey K, Edmiston SN, et al: FAK overexpression and p53 mutations are highly correlated in human breast cancer. Int J Cancer. 125:1735–1738. 2009. View Article : Google Scholar : PubMed/NCBI
3	Olivier M, Eeles R, Hollstein M, et al: The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat. 19:607–614. 2002. View Article : Google Scholar : PubMed/NCBI
4	Kondo I, Iida S, Takagi Y and Sugihara K: MDM2 mRNA expression in the p53 pathway may predict the potential of invasion and liver metastasis in colorectal cancer. Dis Colon Rectum. 51:1395–1402. 2008. View Article : Google Scholar : PubMed/NCBI
5	Sunavala-Dossabhoy G, Palaniyandi S, Clark C, et al: Analysis of eIF4E and 4EBP1 mRNAs in head and neck cancer. Laryngoscope. 121:2136–2141. 2011. View Article : Google Scholar : PubMed/NCBI
6	Singh J, Jayaraj R, Baxi S, Mileva M, Curtin J and Thomas M: An Australian retrospective study to evaluate the prognostic role of p53 and eIF4E cancer markers in patients with head and neck squamous cell carcinoma (HNSCC): study protocol. Asian Pac J Cancer Prev. 14:4717–4721. 2013. View Article : Google Scholar : PubMed/NCBI
7	Yin X, Kim RH, Sun G, Miller JK and Li BD: Overexpression of eukaryotic initiation factor 4E is correlated with increased risk for systemic dissemination in node-positive breast cancer patients. J Am Coll Surg. 218:663–671. 2014. View Article : Google Scholar : PubMed/NCBI
8	Von Pawel J: Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer. 91:E70–E76. 2004.PubMed/NCBI
9	Feng M, Wang W, Fan Z, Fu B, Li J, Zhang S and Lang J: Tumor volume is an independent prognostic indicator of local control in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Radiat Oncol. 8:2082013. View Article : Google Scholar : PubMed/NCBI
10	Greene FL, Page DL, et al: AJCC Cancer Staging Manual. 6th edition. Springer; New York, NY: pp. 47–60. 2002
11	Lee AW, Lin JC and Ng WT: Current management of nasopharyngeal cancer. Semin Radiat Oncol. 22:233–244. 2012. View Article : Google Scholar : PubMed/NCBI
12	Berg M and Soreide K: EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: implications for targeted therapy. Discov Med. 14:207–214. 2012.PubMed/NCBI
13	Baselga J: The EGFR as a target for anticancer therapy - focus on cetuximab. Eur J Cancer. 37:S16–S22. 2001. View Article : Google Scholar
14	Nicholson RI, Gee JM and Harper ME: EGFR and cancer prognosis. Eur J Cancer. 37(Suppl 4): S9–S15. 2001. View Article : Google Scholar : PubMed/NCBI
15	Meek DW: Tumour suppression by p53: a role for the DNA damage response? Nat Rev Cancer. 9:714–723. 2009.PubMed/NCBI
16	Chang LJ and Eastman A: Decreased translation of p21 (waf1) mRNA causes attenuated p53 signaling in some p53 wild-type tumors. Cell Cycle. 11:1818–1826. 2012. View Article : Google Scholar : PubMed/NCBI
17	Seong HA and Ha H: Murine protein serine/threonine kinase 38 activates p53 function through Ser15 phosphorylation. J Biol Chem. 287:20797–20810. 2012. View Article : Google Scholar : PubMed/NCBI
18	Yin Y, Stephen CW, Luciani MG, et al: p53 stability and activity is regulated by mdm2-mediated induction of alternative p53 translation products. Nat Cell Biol. 46:462–467. 2002. View Article : Google Scholar
19	Camus S, Ménendez S, Fernandes K, et al: The p53 isoforms are differentially modified by Mdm2. Cell Cycle. 11:1646–1655. 2012. View Article : Google Scholar : PubMed/NCBI
20	Huang L, Yan Z, Liao X, et al: The p53 inhibitors MDM2/MDMX complex is required for control of p53 activity in vivo. Proc Natl Acad Sci. 108:12001–12006. 2011. View Article : Google Scholar : PubMed/NCBI
21	Nicholson J and Hupp TR: The molecular dynamics of MDM2. Cell Cycle. 9:1878–1881. 2010. View Article : Google Scholar : PubMed/NCBI
22	De Benedetti A and Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene. 23:3189–3199. 2004. View Article : Google Scholar : PubMed/NCBI
23	Zimmer SG, DeBenedetti A and Graff JR: Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res. 20:1343–1351. 2000.PubMed/NCBI
24	Stark AM, Hugo HH, Witzel P, et al: Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir. 64:30–36. 2003. View Article : Google Scholar : PubMed/NCBI
25	Ushio Y, Tada K, Shiraishi S, et al: Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma. Front Biosci. 1:281–288. 2003. View Article : Google Scholar
26	Halatsch ME, Schmidt U, Unterberg A and Vougioukas VI: Uniform MDM2 overexpression in a panel of glioblastoma multiforme cell lines with divergent EGFR and p53 expression status. Anticancer Res. 26:4191–4194. 2006.
27	Pan J, Tang T, Xu L, et al: Prognostic significance of expression of cyclooxygenase-2, vascular endothelial growth factor, and epidermal growth factor receptor in nasopharyngeal carcinoma. Head Neck. 35:1238–1247. 2013. View Article : Google Scholar
28	Esteve A, Lehman T, Jiang W, et al: Correlation of p53 mutations with epidermal growth factor receptor overexpression and absence of mdm2 amplification in human esophageal carcinomas. Mol Carcinog. 8:306–311. 1993. View Article : Google Scholar : PubMed/NCBI
29	Deb SP, Muñoz RM, Brown DR, et al: Wild-type human p53 activates the human epidermal growth factor receptor promoter. Oncogene. 9:1341–1349. 1994.PubMed/NCBI
30	Korkolopoulou P, Christodoulou P, Kouzelis K, et al: MDM2 and p53 expression in gliomas: a multivariate survival analysis including proliferation markers and epidermal growth factor receptor. Br J Cancer. 75:1269–1278. 1997. View Article : Google Scholar : PubMed/NCBI
31	Harada K, Kurisu K, Tahara H, et al: Telomerase activity in primary and secondary glioblastomas multiforme as a novel molecular tumor marker. J Neurosurg. 93:618–625. 2000. View Article : Google Scholar : PubMed/NCBI
32	Halatsch ME, Schmidt U, Botefur IC, et al: Overexpression of deletion-mutant epidermal growth factor receptor is associated with altered genotoxic stress-provoked p53 mRNA induction in a human glioblastoma cell line. Anticancer Res. 21:189–195. 2001.PubMed/NCBI
33	Kleihues P and Ohgaki H: Primary and secondary glioblastomas: from concept to clinical diagnosis. Neuro Oncol. 1:44–51. 1999.
34	Stark AM, Hugo HH, Witzel P, et al: Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir. 64:30–36. 2003. View Article : Google Scholar : PubMed/NCBI
35	Houillier C, Lejeune J, Benouaich-Amiel A, et al: Prognostic impact of molecular markers in a series of 220 primary glioblastomas. Cancer. 106:2218–2223. 2006. View Article : Google Scholar : PubMed/NCBI
36	Dehais C, Laigle-Donadey F, Marie Y, et al: Prognostic stratification of patients with anaplastic gliomas according to genetic profile. Cancer. 107:1891–1897. 2006. View Article : Google Scholar : PubMed/NCBI
37	Ruano Y, Ribalta T, de Lope AR, et al: Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. Am J Clin Path. 131:257–263. 2009. View Article : Google Scholar : PubMed/NCBI
38	Ruiz C, Seibt S, Al Kuraya K, et al: Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int J Cancer. 118:2190–2194. 2006. View Article : Google Scholar
39	Berghmans T, Mascaux C, Haller A, et al: EGFR, TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association. Lung Cancer. 62:35–44. 2008. View Article : Google Scholar : PubMed/NCBI
40	Schaefer IM, Sahlmann CO, Overbeck T, et al: Blastomatoid pulmonary carcinosarcoma: report of a case with a review of the literature. BMC Cancer. 12:4242012. View Article : Google Scholar : PubMed/NCBI
41	Vasei M, Modjtahedi H, Ale-Booyeh O, et al: Amplification and expression of EGFR and ERBB2 in Wilms tumor. Cancer Genet Cytogenet. 194:88–95. 2009. View Article : Google Scholar : PubMed/NCBI
42	Wiseman SM, Masoudi H, Niblock P, et al: Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 14:719–729. 2007. View Article : Google Scholar
43	Baffa R, Letko J, McClung C, LeNoir J, Vecchione A and Gomella LG: Molecular genetics of bladder cancer: targets for diagnosis and therapy. J Exp Clin Cancer Res. 25:145–160. 2006.PubMed/NCBI
44	Bianco R, Caputo R, Caputo R, Damiano V, De Placido S, Ficorella C, et al: Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer. Clin Cancer Res. 10:4858–4864. 2004. View Article : Google Scholar : PubMed/NCBI